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Abstract
Background: National guidelines for sexually transmitted infections (STIs) in primary care exists but 
their management is uncertain.
Aim: To assess the management of STIs against national standards in primary care.
Design & setting: A questionnaire based study in London and Brighton. The survey was conducted in 
2015 following reorganisation of sexual health services in England.
Method: Questionnaires were sent to GPs in London and Brighton about testing for STIs, treatment 
for gonorrhoea, specialist advice, and referral services.
Results: Of 119 GPs who responded, most expressed confidence in treating chlamydia (n = 105/119, 
88%), trichomonas (n = 81/119, 68%), and herpes (n = 82/119, 69%) but not gonorrhoea (n = 32/119, 
27%). Most referred cases of syphilis (n = 92/119, 77%) and genital warts (83/119, 70%) to genito-
urinary medicine (GUM) as per guidance. Most GPs tested for gonorrhoea on patient request (n = 
95/119, 80%), in tandem with chlamydia screening (n = 89/119, 75%), because of high risk status (n 
= 85/119, 71%) and genital symptoms (n = 108/119, 91%). Some GPs (n = 22/119, 18%) sampled 
urine for culture, 53/119 (45%) provided high vaginal swabs (HVS), and 28/119 (24%) provided self-
taken vulvovaginal swabs (STVVS) for culture. These samples are not appropriate for gonococcal 
culture and not processed in the laboratory. Urethral swabs for men and endocervical swabs (ECS) are 
recommended for gonococcus culture. Over half (n = 60/102, 59%) of GPs did not treat gonorrhoea 
but some prescribed cefixime, ciprofloxacin, or azithromycin. Eighty-seven per cent (n = 104/119) 
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sought advice from GUM, and 83/103 (81%) referred gonorrhoea nucleic acid amplification test 
(NAAT)-positive patients.
Conclusion: There is scope for improvement of STIs management in primary care to ensure that 
patients are optimally investigated, treated, and referred.
How this fits in
This scoping survey revealed that GPs were not fully compliant with national guidance for the 
management of STIs in primary care. Most GPs expressed confidence in treating chlamydia, but 
lacked confidence in treating genital gonorrhoea. Urethral swabs (for men) and ECS (for women) are 
recommended for gonococcus culture, but some GPs sent urine for culture and provided high vaginal 
swabs and STVVS for culture, samples which would not be processed in the laboratory. Many GPs refer 
patients for treatment of gonorrhoea but a few inappropriately prescribed cefixime, ciprofloxacin, and 
azithromycin as single agents.
Introduction
Patients with STIs are often managed initially by GPs. Sexual health provision in England has undergone 
major changes following the implementation of the Health and Social Care Act 2012, resulting in shared 
commissioning between NHS England, local authorities, and clinical commissioning groups,1 and 
commissioning of internet-accessible sexual health services.2 London and Brighton have the highest 
and second highest reported rates of sexually transmitted infections in England respectively.3 National 
guidance exists for STIs management in primary care.4 Also, national standards exist for providers 
of sexual health services.5 As many patients still access services provided by GPs, it is important to 
understand how they manage STIs. Wetten et al6 demonstrated the continued use by some GPs of 
antimicrobials no longer recommended for gonorrhoea. It is also pertinent to assess how primary care 
clinicians screen patients for STIs, and utilise laboratory and referral services. The objective of this 
survey was to understand the management of STIs in primary care in London and Brighton, two cities 
with high rates of STIs. The questionnaire concentrated upon six key areas: confidence in treating STIs, 
indications for sampling, sample types, gonorrhoea treatment, accessing clinical advice and referral 
pathways for gonorrhoea.
Method
A questionnaire was developed by collaboration with microbiologists, GUM physicians, a primary care 
facilitator, and GPs to investigate the management of STIs in primary care, focusing on confidence in 
the diagnosis of STIs, indications for sampling, sample types, treatment, accessing clinical advice and 
GUM referral (available from the author on request). The national guidance for sexually transmitted 
infections, developed by the Royal College of General Practitioners and British Association for Sexual 
Health and HIV (BASHH), was used as the standard4 for developing the questionnaire. GPs in London 
and Brighton were targeted, cities which have high rates of STIs.3 All 1406 general practices in London 
and 329 practices in the Brighton area were invited to participate in this survey by email correspondence. 
The letter was distributed via an up-to-date practice directory held by the pathology departments in 
Barts Health NHS Trust London and Royal Sussex County Hospital,Brighton. The message explained 
that the questionnaire required a response from GPs on their management of STIs with emphasis on 
Neisseria gonorrhoeae. The email stated that individuals presenting at risk of an STI, with or without 
symptoms, are increasingly seen in primary care. The survey examined the care of patients with STIs 
in collaboration with the local GUM service. It was stated that BASHH has developed guidance on 
STIs in primary care, and standards have been developed to support all providers of sexual health 
services in achieving safe, high quality services for the management of STIs. An electronic link to 
the ‘select survey’ tool provided access to the questionnaire, which comprised 16 questions. Fifteen 
questions were closed-ended and one was open-ended. Some of the questions had a tabular format, 
with multiple rows and columns which required a tick box reply. Five of the closed-ended questions 
also had one stem for open-ended replies. Each question required a response before the individual 
could respond to the next question. Potential response bias was addressed by improving the clarity 
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and length of the questions, by avoiding leading questions, using simple and precise language, and 
by ensuring the questions considered the target audience. Selection bias was avoided by sending 
the questionnaire to all the practices in London and Brighton. As achieving a 10%–15% response 
rate was anticipated to be challenging, all GPs in London and Brighton were targeted. Potential 
confounding was determined by testing the questionnaire with GPs and developing the questionnaire 
using key stakeholders from microbiology, GUM, and the primary care facilitator and by avoiding 
specific requested values and using categories. The survey would take 5 minutes to complete and the 
responses were anonymised. The select survey tool is widely used within Public Health England and 
the questionnaire was available for 3 months for completion. The questionnaire was sent to general 
practices in London five times and in Brighton twice in 2015–2016.
Results
Of 164 GPs who accessed the questionnaire, a maximum of 119 responded adequately to survey 
questions. As seen in the tables below, some responders did not address all the questions and some 
of the sections within each question were incomplete.
As shown in Table 1, confidence for treating gonorrhoea varied by STIs, with a larger proportion 
of GPs being confident for treating chlamydia , trichomonas, and genital herpes compared to genital 
and extragenital gonorrhoea, genital warts, and syphilis. This pattern was reflected in the number of 
responders seeking specialist advice and referral to GUM.
The majority of GPs tested for gonococcus upon patient request, as part of chlamydia screening 
(n = 89/119, 75%), due to high risk status or presence of genital symptoms but fewer tested for 
extragenital symptoms (Table 2).
Eighteen GPs (15%) reported that they would take urethral swabs and 43/119 (35%) would submit 
urine for NAAT (Table 3). Fifty-seven (48%) reported that they would not routinely test for gonorrhoea 
(Table  3). However, 44/119 (37%) GPs submit ECS, 25/119 (21%) HVS, and 43/119 (36%) STVVS 
(Table 3).
Only 102 responded to the question on whether they prescribed antibiotic treatment for gonorrhoea 
infection. Many GPs (n = 60, 59%) would not prescribe treatment. When asked about the antibiotic 
selection for treating gonorrhoea, there were 23/106 conditional responses and choices varied 
from cefixime with or without azithromycin, ceftriaxone with or without azithromycin, ciprofloxacin, 
ofloxacin, azithromycin, seeking advice from GUM, or looking at guidelines.
There were 14 respondents who did not complete the questionnaire and only responded to the 
first four questions, and one individual completed seven questions. The numbers were too small for a 
meaningful comparison between the two groups.
Seventy-six of the 103 (74%) reported a process for ensuring that partners of gonorrhoea-positive 
patients received treatment.
Most GPs obtained information on STIs (Figure 1) and clinical advice (Table 4) from the GUM 
service.
Discussion
Summary
This general practice-based scoping survey in London and Brighton provides information on confidence 
in treating STIs, indications for sampling, sample types, treatment for gonorrhoea, and accessing 
clinical advice and referral pathways for STIs diagnosed in the community. From the 1735 GP practices 
contacted, 119 GPs responded to the questionnaire. There was marked heterogeneity in confidence 
and knowledge in the management of STIs and better use of the national guidance would improve 
the management of these infections in the community. As screening for chlamydia is encouraged in 
the community,7 confidence in managing patients with chlamydia was found to be high. There was less 
confidence in managing gonorrhoea; a large number of GPs would refer cases of gonorrhoea, especially 
extragenital gonorrhoea, to GUM, which is in line with national guidance. Likewise, cases of syphilis 
and genital warts would be referred to GUM, but few would refer trichomonas to GUM, perhaps as 
treatment is considered straightforward with metronidazole. , GUM referral is, however, preferable to 
enable the screening of coexisting STIs. There was confusion regarding the sample types required for 
molecular diagnosis and those required for culture of gonorrhoea. ECS (recommended for gonococcal 
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culture8,9 were still regarded a useful sample type 
for gonococcal NAAT testing (37%) when STVVS 
would suffice. Although urine is suitable in men 
for gonococcal NAATs,8 this was not understood 
by over half of the responders, and some GPs 
continue to send urine for gonococcal culture, 
which is not recommended.9 A large number of 
GPs opted not to treat gonorrhoea in general 
practice; if they did, cefixime, ciprofloxacin, or 
azithromycin were considered for treatment, 
which is not in line with the primary care national 
guidance.4
Advice embedded within electronic requesting 
was popular amongst responders and access to 
antibiotic treatment guidance with regular reviews would benefit antimicrobial stewardship within the 
community.
There was good evidence that gonococcal NAAT-positive patients and their contacts would be 
referred to GUM in line with national guidance.4
Strengths and limitations
A strength of this scoping exercise was the use of national guidance as a standard developed for 
STIs in the evaluation of these findings. The questionnaire was comprehensive, with provision for 
comments, and covered key areas of management of these patients in primary care.
However, this scoping exercise highlighted several limitations. Although designed for GPs, 
participant anonymity means that other practice staff might have completed the questionnaire. This 
may explain discrepancies in the numbers of responders for different questions. A follow-up study 
should focus on key questions. Another limitation was the inability to differentiate between responses 
from Brighton and London, which limited analysis.
The national guidance for STIs management in primary care was not provided in the mailshots 
and some participants might not have been aware of it. Some GPs might have presumed the BASHH 
guidance in the mailshot to be secondary care guidance, and this might have affected responses 
to questions. Provision of the guidance document might have improved the completeness of the 
survey and the response rate. Question clarity might have been improved by substituting the word 
‘testing’ for ‘screening’, and by providing a definition for ‘high risk’. It may be that some GPs test and 
treat some patients in the community and then refer to GUM for further follow up, but this was not 
captured in this study.
Table 2 Responders’ indicators for testing for 
gonococcus in general practice
What are the usual indicators for 
gonococcus testing in your prac-
tice? n (%)
Patient requests the test 95 (80)
Part of chlamydia screening 89 (75)
High-risk patient 85 (71)
Symptomatic, genital symptoms 108 (91)
Symptomatic, extragenital symptoms 42 (35)
Other, please specify 7 (6)
Table 3 Responder answers to the question ‘What sample types do you routinely take for gonococ-
cus testing?’ (n = 119)
Sample type
Specimen for 
MC&S for gonor-
rhoea, % (n)
Specimen for 
NAATs for gonor-
rhoea, % (n)
Samples not 
routinely taken for 
gonorrhoea, % (n)
Responses 
total, n
Urethral swab 22 (28) 14 (18) 63 (79) 125
High vaginal swab 42% (53) 20 (25) 38 (47) 125
Self-taken vulvovaginal swab 23 (28) 35 (43) 42 (51) 122
Endocervical swab 38 (47) 36 (44) 26 (32) 123
Throat swab 9 (11) 8 (10) 82 (98) 119
Rectal swab 10 (12) 11 (13) 79 (95) 120
First pass urine 18 (22) 35 (43) 47 (57) 122
Proportions may not add up to 100 due to rounding of numbers. NAAT = nucleic acid amplification test. 
MC&S = microscopy, culture and sensitivity
Dave J et al. BJGP Open 2019; DOI: 10.3399/bjgpopen18X101639
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Despite repeated attempts to encourage participation only 119 responses were received from the 
more than 1000 practices in London and Brighton. Unfortunately, this is not surprising given the many 
competing demands on time in general practice. The results provided should thus be interpreted as 
merely applying to the practices from which the information was collected. Differences in the number 
of emails to GPs in the two areas reflected local communication practices. This represented a potential 
source of bias in interpretation of the results.
Comparison with existing literature
From 1735 general practices in London and Brighton, 119 responses were obtained. This may be 
because some GPs may not have seen or been aware of the questionnaire as it was sent electronically 
as a link. It is difficult to give an indication of how representative the sampling frame was to provide 
a definite understanding of the management of STIs. While the findings may not reliably represent 
practice and knowledge in the wider community, some clear learning points emerged regarding the 
management of STIs.
GPs reported varying levels of confidence and knowledge in managing STIs in general practice. 
Whilst levels of confidence were high for chlamydia, lower levels of confidence were found for 
gonorrhoea. A large number of GPs were confident about treating genital herpes and this may reflect 
the more frequent requirement to treat recurrent rather than primary genital herpes infection. Most 
GPs were confident about management of patients with trichomonas infection. However, the increasing 
availability of molecular tests for trichomonas, the poor performance characteristics of trichomonas 
culture and its main utility in patients from a high-risk population (for example, Black African),10 and 
the investigation of coexisting STIs would suggest that GUM referral would be beneficial to patients. 
Most GPs would refer syphilis and genital warts cases to GUM, as advised by the guidance,4 reflecting 
the complexity in the management of these cases.
There was some evidence of confusion regarding the testing of patients for gonorrhoea and 
their treatment and referral. National guidance recommends NAAT to investigate suspected cases 
of gonorrhoea. Despite evidence that STVVS are non-inferior to ECS and high vaginal swabs for 
NAAT,8,11 37% of GPs submitted ECS, possibly because this is the recommended sample type for 
culture.8,10 National guidance4 recommends culture of NAAT-positive patients in order to determine 
antibiotic susceptibilities. For women, only 45% of GPs would submit ECS for culture, possibly 
because of confusion with guidance for NAAT samples. In men, urethral swabs are recommended for 
Figure 1  Responses to the question ‘Are you aware of any of the following sources of information on sexually transmitted infections and do you find 
them useful?’
GUM = genito-urinary medicine. STI = sexually transmitted infection.
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gonococcal culture but, surprisingly, 18% of GPs 
stated they would submit urine samples, possibly 
because urine is a suitable sample type for 
NAAT. Gonococcus is a fragile organism and the 
laboratory recovery rate12 is poor with increased 
transport time. GPs may not be aware that 
successful culture is very dependent on getting 
the sample to the laboratory quickly.12
A considerable number of GPs said their 
practice would not prescribe treatment for 
gonorrhoea in accordance with national 
guidance,4 which advises referral to GUM unless 
this is difficult to arrange. Some replies complied 
with the use of recommended antibiotics for 
treating gonorrhoea, but a few GPs would 
use cefixime, ciprofloxacin, and azithromycin, 
suggesting that information about antibiotic 
treatment with regular updates may improve 
prescribing particularly as the majority of the 
GPs wanted advice embedded within electronic 
requesting. A recent study found that only 1.7% 
(n = 34/1956) of all gonorrhoea cases were 
diagnosed in primary care and there was high 
correct pathway management.13
Changes in STI guidance (for example, BASHH 
chlamydia treatment guidelines)14 present 
primary care services with the challenge of 
keeping up to date. This may cause variation in 
treatment guidance followed by different local 
health institutions.
Reports of the emergence of multi-drug 
resistance in Neisseria gonorrhoeae15 emphasises 
the importance of gonococcal treatment 
guidance with regular reviews thus improving 
antimicrobial stewardship in the community.
Reassuringly, most GPs would not consider 
management in the community of patients and 
their contacts with gonorrhoea who were NAAT-
positive, and would refer to GUM, in accordance 
with national guidance4 and helping to reduce 
further selection pressure for antimicrobial 
resistance.
Implications for research and prac-
tice
In a changing landscape of provision of care for 
STIs, these results suggest areas for targeted education and training in the management of STIs 
among GPs. Future work could involve a different study design with an interview process involving 
key questions, improved by addressing the limitations discussed above, with a limited number of GPs. 
This would provide meaningful data for analysis and potentially improve the management of these 
patients.
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Table 4 Results regarding access to clinical ad-
vice, management of patients with gonococcal 
positive NAATs, and referral pathway for GUM
When seeking advice on STI, who would 
you contact? n (%)
GUM 104 (87)
Primary care colleague 30 (25)
Primary care facilitator 1 (1)
Ask a colleague 17 (14)
BNF 39 (33)
Phone microbiologist 33 (28)
Other, please specify 4 (3)
Total responses, n 119
What form of real time clinical advice on 
sexual health/STI would you find most 
helpful?
Online electronic messaging service to 
lab consultants e.g. kinesis, email 45 (42)
Advice embedded within electronic 
requesting (e.g. sample or test choice), 
or reporting (e.g. antibiotic choice) 
systems 88 (83)
Information leaflet on the management 
of gonorrhoea 31 (29)
Clinical advice by telephone on a 
positive result/confirmation 66 (62)
Other, please specify 7 (7)
Total responses, n 106
With reference to the management of 
patients with suspected gonorrhoea (ie, 
they have positive molecular NAAT test) 
do you ... ?
Refer all patients 83 (81)
Refer only complicated cases of 
infection to a GUM clinic 16 (16)
Treat all patients at surgery 4 (4)
Total responses, n 103
BNF = British National Formulary. GUM = genito-
urinary medicine. HIV= human immunodeficiency 
virus. NAAT = nucleic acid amplification test. STI = 
sexually transmitted infection.
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